Adial pharmaceuticals granted key patent from the united states patent and trademark office

Glen allen, va., april 22, 2024 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued april 16, 2024 by the united states patent and trademark office. this patent expands adial's intellectual property protection and covers the combination of the company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (aud) and other drug dependencies, such as opioid use disorder (oud), with the company's lead investigational new drug product ad04.
ADIL Ratings Summary
ADIL Quant Ranking